Thiazolidinedione use is associated with reduced risk of Parkinson’s disease in patients with diabetes: a meta-analysis of real-world evidence

Salman Hussain(European CanCer Organisation), Benny Antony(University of Tasmania), John Burgess(Torrens University Australia), Harveen Baxi, Bruce Taylor(University of London), Ambrish Singh

Neurological Sciences

June 9, 2020

10.1007/s10072-020-04494-3

Cited by 29

Related Papers

Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019

|The Lancet|2021|1.7k

Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021

|The Lancet Rheumatology|2023|1.7k

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

|Neurology|2014|1.3k

Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021

|The Lancet Rheumatology|2023|632

Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis

|Annals of Neurology|2010|453